Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focusing on creating value for people living with neurology and immunology conditions.
Celebrating 90 years of innovation #UCB90
Twitter Feed
-
When people think of clinical studies they often imagine something that only includes scientists. The truth is that everyone can be a part of a trial and help to find solutions to treat severe diseases. Find out more here #UCB90 #ClinicalStudies https://t
— UCB News (@ucb_news) 11.12.2018 -
Understanding and shaping knowledge about disease mechanisms is critical to advancing breakthrough treatment choices. Thus, sharing and co-creating knowledge with our patients ???? is one of the main innovative methods we use to ensure the quality of care
— UCB News (@ucb_news) 07.12.2018 -
We are passionate about making a genuine difference in the lives of patients and their families in a caring and socially responsible manner????????. Check out how we put this into practice #UCB90 #CSR https://t.co/2Vm4Djelqb https://t.co/3SsrlnMCul
— UCB News (@ucb_news) 05.12.2018
Highlights
At UCB, we take our responsibility to the planet very seriously.
UCB Ventures, a strategic corporate venture fund established in 2017 to further strengthen UCB’s ability to create value from novel insights and technologies that can transform the lives of patients suffering from severe diseases, has announced its first direct investment.
